Document is current

Any future updates will be listed below

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model

Crossref DOI link: https://doi.org/10.1007/s00277-025-06560-2

Published Online: 2025-12-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark